A role for the mitochondrial pyruvate carrier as a repressor of the warburg effect and colon cancer cell growth

Molecular Cell

Volumn 56, Issue 3, 2014, Pages 400-413

  Schell, John C ^a   Olson, Kristofor A ^a   Jiang, Lei ^b   Hawkins, Amy J ^a   VanVranken, Jonathan G ^a   Xie, Jianxin ^c   Egnatchik, Robert A ^b   Earl, Espen G ^a   DeBerardinis, Ralph J ^b   Rutter, Jared ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CELL SIGNALING TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; MITOCHONDRIAL PYRUVATE CARRIER 1; MITOCHONDRIAL PYRUVATE CARRIER 2; MONOCARBOXYLATE TRANSPORTER; UNCLASSIFIED DRUG; ANION TRANSPORT PROTEIN; CARRIER PROTEIN; MITOCHONDRIAL PROTEIN; MPC1 PROTEIN, HUMAN; MPC2 PROTEIN, HUMAN;

ARTICLE; BIOCHEMISTRY; CANCER GROWTH; CANCER PROGNOSIS; CELL CULTURE; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; METABOLISM; MULTIPLE CANCER; OXIDATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; STEM CELL; WARBURG EFFECT; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; COLON TUMOR; GLYCOLYSIS; HEK293 CELL LINE; HT 29 CELL LINE; MITOCHONDRION; NUDE MOUSE; OXIDATION REDUCTION REACTION;

ANIMALS; ANION TRANSPORT PROTEINS; CELL PROLIFERATION; COLONIC NEOPLASMS; GLYCOLYSIS; HEK293 CELLS; HT29 CELLS; HUMANS; MICE, NUDE; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MITOCHONDRIAL PROTEINS; NEOPLASM TRANSPLANTATION; OXIDATION-REDUCTION;

EID: 84922445353     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2014.09.026     Document Type: Article

References (79)

1. Aguirre-Gamboa R., Gomez-Rueda H., Martínez-Ledesma E., Martínez-Torteya A., Chacolla-Huaringa R., Rodriguez-Barrientos A., Tamez-Peña J.G., Treviño V. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 2013, 8:e74250.
2. Azuma M., Shi M., Danenberg K.D., Gardner H., Barrett C., Jacques C.J., Sherod A., Iqbal S., El-Khoueiry A., Yang D., et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics 2007, 8:1705-1713.
3. Bassenge E., Sommer O., Schwemmer M., Bünger R. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state. Am. J. Physiol. Heart Circ. Physiol. 2000, 279:H2431-H2438.
4. Bayley J.P., Devilee P. The Warburg effect in 2012. Curr. Opin. Oncol. 2012, 24:62-67.
5. Bignone P.A., Lee K.Y., Liu Y., Emilion G., Finch J., Soosay A.E.R., Charnock F.M.L., Beck S., Dunham I., Mungall A.J., Ganesan T.S. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 2007, 26:683-700.
6. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Bonnet S., et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
7. Bricker D.K., Taylor E.B., Schell J.C., Orsak T., Boutron A., Chen Y.C., Cox J.E., Cardon C.M., Van Vranken J.G., Dephoure N., et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 2012, 337:96-100.
8. Cai H., Kumar N., Ai N., Gupta S., Rath P., Baudis M. Progenetix: 12 years of oncogenomic data curation. Nucleic Acids Res. 2014, 42(Database issue):D1055-D1062.
9. Cao F., Wagner R.A., Wilson K.D., Xie X., Fu J.D., Drukker M., Lee A., Li R.A., Gambhir S.S., Weissman I.L., et al. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS ONE 2008, 3:e3474.
10. Carpentino J.E., Hynes M.J., Appelman H.D., Zheng T., Steindler D.A., Scott E.W., Huang E.H. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009, 69:8208-8215.
11. Cavalli L.R., Varella-Garcia M., Liang B.C. Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ. 1997, 8:1189-1198.
12. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Disc. 2012, 2:401-404.
13. Chen R., Bronner M.P., Crispin D.A., Rabinovitch P.S., Brentnall T.A. Characterization of genomic instability in ulcerative colitis neoplasia leads to discovery of putative tumor suppressor regions. Cancer Genet. Cytogenet. 2005, 162:99-106.
14. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
15. Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., Cantley L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-186.
16. Chute J.P., Muramoto G.G., Whitesides J., Colvin M., Safi R., Chao N.J., McDonnell D.P. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 2006, 103:11707-11712.
17. Colca J.R., McDonald W.G., Cavey G.S., Cole S.L., Holewa D.D., Brightwell-Conrad A.S., Wolfe C.L., Wheeler J.S., Coulter K.R., Kilkuskie P.M., et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One 2013, 8:e61551.
18. Deng Y., Zhou J., Fang L., Cai Y., Ke J., Xie X., Huang Y., Huang M., Wang J. ALDH1 is an independent prognostic factor for patients with stages II-III rectal cancer after receiving radiochemotherapy. Br. J. Cancer 2014, 110:430-434.
19. Divakaruni A.S., Wiley S.E., Rogers G.W., Andreyev A.Y., Petrosyan S., Loviscach M., Wall E.A., Yadava N., Heuck A.P., Ferrick D.A., et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. USA 2013, 110:5422-5427.
20. Eboli M.L., Paradies G., Galeotti T., Papa S. Pyruvate transport in tumour-cell mitochondria. Biochim. Biophys. Acta 1977, 460:183-187.
21. Fathi A., Hatami M., Hajihosseini V., Fattahi F., Kiani S., Baharvand H., Salekdeh G.H. Comprehensive gene expression analysis of human embryonic stem cells during differentiation into neural cells. PLoS ONE 2011, 6:e22856.
22. Folmes C.D., Nelson T.J., Dzeja P.P., Terzic A. Energy metabolism plasticity enables stemness programs. Ann. N Y Acad. Sci. 2012, 1254:82-89.
23. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
24. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6. pl1-pl1.
25. Garon E.B., Christofk H.R., Hosmer W., Britten C.D., Bahng A., Crabtree M.J., Hong C.S., Kamranpour N., Pitts S., Kabbinavar F., et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2014, 140:443-452.
26. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
27. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating invivo. J. Exp. Med. 1996, 183:1797-1806.
28. Gotanda Y., Akagi Y., Kawahara A., Kinugasa T., Yoshida T., Ryu Y., Shiratsuchi I., Kage M., Shirouzu K. Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor. Anticancer Res. 2013, 33:2941-2947.
29. Halestrap A.P. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem. J. 1975, 148:85-96.
30. Hamanaka R.B., Chandel N.S. Targeting glucose metabolism for cancer therapy. J. Exp. Med. 2012, 209:211-215.
31. Olszewski U., Poulsen T.T., Ulsperger E., Poulsen H.S., Geissler K., Hamilton G. Invitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin. Pharmacol. 2010, 2:177-183.
32. Haraguchi N., Utsunomiya T., Inoue H., Tanaka F., Mimori K., Barnard G.F., Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24:506-513.
33. Herzig S., Raemy E., Montessuit S., Veuthey J.L., Zamboni N., Westermann B., Kunji E.R., Martinou J.C. Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012, 337:93-96.
34. Hong Y., Ho K.S., Eu K.W., Cheah P.Y. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Clin. Cancer Res. 2007, 13:1107-1114.
35. Huang C.Y., Kuo W.T., Huang Y.C., Lee T.C., Yu L.C. Resistance to hypoxia-induced necroptosis is conferred by glycolytic pyruvate scavenging of mitochondrial superoxide in colorectal cancer cells. Cell Death Dis. 2013, 4:e622.
36. Ito K., Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat. Rev. Mol. Cell Biol. 2014, 15:243-256.
37. Kang Y.H., Chung S.J., Kang I.J., Park J.H., Bünger R. Intramitochondrial pyruvate attenuates hydrogen peroxide-induced apoptosis in bovine pulmonary artery endothelium. Mol. Cell. Biochem. 2001, 216:37-46.
38. Kaplon J., Zheng L., Meissl K., Chaneton B., Selivanov V.A., Mackay G., van der Burg S.H., Verdegaal E.M., Cascante M., Shlomi T., et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013, 498:109-112.
39. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
40. Koukourakis M.I., Giatromanolaki A., Sivridis E., Bougioukas G., Didilis V., Gatter K.C., Harris A.L. Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br. J. Cancer 2003, 89:877-885. Tumour and Angiogenesis Research Group.
41. Le Floch R., Chiche J., Marchiq I., Naiken T., Ilc K., Murray C.M., Critchlow S.E., Roux D., Simon M.P., Pouysségur J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc. Natl. Acad. Sci. USA 2011, 108:16663-16668.
42. Li C.L., Wang M., Ma X.Y., Zhang W. NRGA1, a putative mitochondrial pyruvate carrier, mediates ABA regulation of guard cell ion channels and drought stress responses in Arabidopsis. Mol. Plant 2014, 7:1508-1521.
43. Liu Y., Emilion G., Mungall A.J., Dunham I., Beck S., Le Meuth-Metzinger V.G., Shelling A.N., Charnock F.M.L., Ganesan T.S. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. Oncogene 2002, 21:387-399.
44. Liu P.P., Liao J., Tang Z.-J., Wu W.-J., Yang J., Zeng Z.-L., Hu Y., Wang P., Ju H.-Q., Xu R.-H., Huang P. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ. 2014, 21:124-135.
45. Luo W., Semenza G.L. Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011, 2:551-556.
46. Mandal S., Lindgren A.G., Srivastava A.S., Clark A.T., Banerjee U. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Stem Cells 2011, 29:486-495.
47. McFate T., Mohyeldin A., Lu H., Thakar J., Henriques J., Halim N.D., Wu H., Schell M.J., Tsang T.M., Teahan O., et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem. 2008, 283:22700-22708.
48. Michelakis E.D., Sutendra G., Dromparis P., Webster L., Haromy A., Niven E., Maguire C., Gammer T.L., Mackey J.R., Fulton D., et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci. Transl. Med. 2010, 2:31ra34.
49. Morais R., Zinkewich-Péotti K., Parent M., Wang H., Babai F., Zollinger M. Tumor-forming ability in athymic nude mice of human cell lines devoid of mitochondrial DNA. Cancer Res. 1994, 54:3889-3896.
50. Network T.C.G.A. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
51. Papa S., Paradies G. On the mechanism of translocation of pyruvate and other monocarboxylic acids in rat-liver mitochondria. Eur. J. Biochem. 1974, 49:265-274.
52. Paradies G., Capuano F., Palombini G., Galeotti T., Papa S. Transport of pyruvate in mitochondria from different tumor cells. Cancer Res. 1983, 43:5068-5071.
53. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res. 2005, 65:6207-6219.
54. Patterson J.N., Cousteils K., Lou J.W., Manning Fox J.E., MacDonald P.E., Joseph J.W. Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated insulin secretion. J. Biol. Chem. 2014, 289:13335-13346.
55. Pinheiro C., Longatto-Filho A., Scapulatempo C., Ferreira L., Martins S., Pellerin L., Rodrigues M., Alves V.A.F., Schmitt F., Baltazar F. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch. 2008, 452:139-146.
56. Pinto M., Appay M.D., Simon-Assmann P., Chevalier G., Dracopoli N., Fogh J., Zweibaum A. Enterocytic Differentiation of cultured human colon cancer cells by replacement of glucose by galactose in the medium. Biol. Cell 1982, 44:193-196.
57. Pratt M.L., Roche T.E. Mechanism of pyruvate inhibition of kidney pyruvate dehydrogenasea kinase and synergistic inhibition by pyruvate and ADP. J. Biol. Chem. 1979, 254:7191-7196.
58. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
59. Rohatgi N., Aly H., Marshall C.A., McDonald W.G., Kletzien R.F., Colca J.R., McDaniel M.L. Novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets. PLoS One 2013, 8:e62012.
60. Sánchez-Aragó M., Chamorro M., Cuezva J.M. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010, 31:567-576.
61. Schieke S.M., Ma M., Cao L., McCoy J.P., Liu C., Hensel N.F., Barrett A.J., Boehm M., Finkel T. Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J. Biol. Chem. 2008, 283:28506-28512.
62. Shahrzad S., Lacombe K., Adamcic U., Minhas K., Coomber B.L. Sodium dichloroacetate (DCA) reduces apoptosis in colorectal tumor hypoxia. Cancer Lett. 2010, 297:75-83.
63. Shyh-Chang N., Locasale J.W., Lyssiotis C.A., Zheng Y., Teo R.Y., Ratanasirintrawoot S., Zhang J., Onder T., Unternaehrer J.J., Zhu H., et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 2013, 339:222-226.
64. Slattery M.L., Lundgreen A., Herrick J.S., Wolff R.K. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat. Res. 2011, 706:13-20.
65. Takaishi S., Okumura T., Tu S., Wang S.S.W., Shibata W., Vigneshwaran R., Gordon S.A.K., Shimada Y., Wang T.C. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006-1020.
66. Tennant D.A., Durán R.V., Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010, 10:267-277.
67. Tibiletti M.G., Trubia M., Ponti E., Sessa L., Acquati F., Furlan D., Bernasconi B., Fichera M., Mihalich A., Ziegler A., et al. Physical map of the D6S149-D6S193 region on chromosome 6Q27 and its involvement in benign surface epithelial ovarian tumours. Oncogene 1998, 16:1639-1642.
68. Timón-Gómez A., Proft M., Pascual-Ahuir A. Differential regulation of mitochondrial pyruvate carrier genes modulates respiratory capacity and stress tolerance in yeast. PLoS ONE 2013, 8:e79405.
69. Vander Heiden M.G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 2011, 10:671-684.
70. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
71. Wanet A., Arnould T., Renard P., Lou P.H., Peterson N. Mitochondrial involvement in stemness and stem cell differentiation. Cellular Bioenergetics in Health and Disease: New Perspective in Mitochondrial Biology 2012, 195-215. Research Signpost, Kerala. P.-H. Lou, N. Petersen (Eds.).
72. Wang X., Perez E., Liu R., Yan L.J., Mallet R.T., Yang S.H. Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells. Brain Res. 2007, 1132:1-9.
73. Wang Y.-C., Yo Y.-T., Lee H.-Y., Liao Y.-P., Chao T.-K., Su P.-H., Lai H.-C. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am. J. Pathol. 2012, 180:1159-1169.
74. Warburg O., Wind F., Negelein E. The Metabolism of Tumors in the Body. J. Gen. Physiol. 1927, 8:519-530.
75. Whitehouse S., Cooper R.H., Randle P.J. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem. J. 1974, 141:761-774.
76. Wu C., Wei Q., Utomo V., Nadesan P., Whetstone H., Kandel R., Wunder J.S., Alman B.A. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res. 2007, 67:8216-8222.
77. Yang W., Xia Y., Ji H., Zheng Y., Liang J., Huang W., Gao X., Aldape K., Lu Z. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 2011, 480:118-122.
78. Yeh C.-S., Wang J.-Y., Chung F.-Y., Lee S.-C., Huang M.-Y., Kuo C.-W., Yang M.-J., Lin S.-R. Significance of the glycolytic pathway and glycolysis related-genes in tumorigenesis of human colorectal cancers. Oncol. Rep. 2008, 19:81-91.
79. Zu X.L., Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 2004, 313:459-465.